Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma

NCT02818023 is registered in ClinicalTrials.gov with Yana Najjar as lead sponsor.

NCT NCT02818023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02818023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Lead sponsor
Yana Najjar
Phase
Phase 1
Overall status
Terminated
Start date
July 13, 2016
Completion date
April 23, 2021
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma